Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Here Comes MISA: China Medical Insurance Agency Starts Off

Executive Summary

The first ever agency devoted to medical insurance in China, MISA is potentially on track to become a major player in drug price negotiation, reimbursement level setting, and drug and device bidding in the country.

You may also be interested in...



Approval For Access? Decoding The Significance Of China’s Opdivo Opening

First comes the approval, then market access. A rapid regulatory clearance for BMS’s Opdivo in China not only pioneers a new and potentially huge market for immuno-oncology treatments, but may potentially set an example in how to expand market access for many new therapies waiting to get into the country, amid multiple recent regulatory and policy changes.

China Zero Tariffs For Cancer Drugs Precede High-Stakes Trade Talks

China is opening up its domestic pharma market with an import duty exemption on 28 drugs including anticancers, effective May. The duty cuts came ahead of the latest trade talks between the US and China, though Chinese officials have underscored that countries like India could also stand to gain.

BeiGene/BMS Parting Abraxane Ways As China Supply Woes Continue

The latest development over the licensing arrangement for the anticancer drug may deal a further blow to BeiGene’s oncology commercial efforts in China.

Topics

UsernamePublicRestriction

Register

PS123212

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel